M onocytes replenish resident macrophages under normal conditions but also move to sites of infection in tissues and differentiate into macrophages in response to immune stimulation. Classically, monocytes may become type M1 macrophages when stimulated through TLRs, CD14, or GM-CSF or become M2 macrophages when stimulated with IL-4 and IL-13 or M-CSF (1-3). However, macrophages have a high degree of plasticity and are profoundly affected by tissue-specific immune-modulating cytokines. Macrophages efficiently respond to environmental signals that change their phenotype and physiology. There is an increasing perception of macrophages as plastic cells that may evolve into a broad spectrum of cell populations depending on the surrounding cytokine environment (4) . Indeed, the stimulation of monocytes with a combination of IL-12 and IL-18 (IL-12/IL-18), but not separately, triggers the survival and differentiation of monocytes to macrophages through an inflammatory pathway different from the classical M1 and M2 pathways (5, 6) . IL-12/IL-18 also induce the release of a unique pattern of cytokines (IL-8, CCL22, CXCL-9, and CXCL10) that is different from the pattern given by other polarizing stimuli such as GM-CSF or IFN-g (1) . IL-12 appears to cooperate or act synergistically with IL-18 in the control of intracellular parasite infection of macrophages (7) or bridging innate and adaptive immunity (8) (9) (10) . Notably, treatment of differentiated macrophages with IL-12/ IL-18 but not with M-CSF induces the production of IFN-g (5, 6, 11) .
Monocytes are usually resistant to HIV-1 infection but when differentiated into macrophages with M-CSF they become highly susceptible (12) . Macrophages are one of the major reservoirs of the HIV type (HIV-1) infection. Once infected, monocyte-derived macrophages (MDM) survive and produce high amounts of viral particles (13) .
The importance of macrophages in HIV-1 infection is also highlighted by the discovery of cellular restriction factors found in myeloid cells that protect target cells against viral infections, including HIV-1. A number of host factors alter the expression of HIV receptors and coreceptors, modulate the attachment and entry of virus particles into cells, or restrict HIV replication inside the cell (14) . Among these cellular host factors, the sterile a motif and HD domain-containing protein-1 (SAMHD1) regulates the 29-deoxynucleoside 59-triphosphate (dNTP) pool in MDM, inhibiting the activity of the HIV-1 reverse transcriptase (15) (16) (17) . SAMHD1 is counteracted by the lentiviral protein Vpx, which is encoded by some SIV strains and HIV-2, but not by HIV-1. Vpx targets SAMHD1 for proteosomal degradation, leading to increased concentration of dNTP and therefore higher levels of HIV-1 replication and virus production (15) (16) (17) (18) .
In this study, we show that macrophages differentiated in the presence of IL-12/IL-18 were resistant to HIV-1 infection inde-pendently of HIV-1 coreceptor expression. Moreover, IL-12/IL-18 blocked HIV-1 replication in already differentiated, HIV-1 susceptible, M-CSF MDM. Expression of SAMHD1 was found upregulated in IL-12/IL-18 MDM and, importantly, the downregulation of this restriction factor with RNA interference or by treatment with viral-like particles (VLP) carrying SIV Vpx protein restored HIV-1 infectivity of IL-12/IL-18 MDM. The IL-12/IL-18-mediated upregulation of SAMHD1 was not prevented by an anti-IFN-g neutralizing Ab, suggesting that its effect was independent of IFN-g production. HIV-1 + individuals show skewed expression of IL-12/IL-18 (19) . Thus, IL-12 and IL-18 may contribute to the immune response against HIV-1 infection.
Materials and Methods

Monocytes isolation and macrophage differentiation
PBMC were obtained and differentiated to macrophages as described before (20, 21) . Briefly, PBMC were obtained from blood of healthy donors using a Ficoll-Paque density gradient centrifugation. To obtain the monocyte population, 300 million PBMC were blocked with an anti-CD32 Ab (StemCell Technologies, Vancouver, BC, Canada) and monocytes were separated by a negative selection Ab mixture (StemCell Technologies) supplemented with an anti-CD41 Ab (StemCell Technologies) to eliminate platelets or by positive selection using Miltenyi MACS CD14 microbeads (Miltenyi Biotec, Madrid, Spain). The purity of the monocyte isolates was confirmed by flow cytometry staining with a combination of CD14, CD3, CD19, and CD16 Abs (Dako, Barcelona, Spain), analyzed in a FACSCalibur flow cytometer (BD Biosciences, Oxford, U.K.). Platelets were not detected in cell cultures (data not shown). Monocytes were resuspended in complete culture medium: RPMI 1640 medium (Life Technologies, Madrid, Spain) supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin. Monocytes were differentiated for 5-7 d at 50 3 10 3 cells/well in 96-well plates or 1 3 10 6 cells/well in 24-well plates in the presence of M-CSF (PeproTech, London, U.K.) at 20 U/ ml (100 ng/ml) or a combination of IL-12 (100 ng/ml; PeproTech) and IL-18 (100 ng/ml; Bionova, Madrid, Spain). When appropriate, differentiated macrophages were culture in the presence of IFN-g (100 ng/ml), GM-CSF (100 ng/ml) and IL-4 (250 ng/ml), or TNF-a (100 ng/ml) (all from PeproTech).
RNA interference
Monocytes were transfected with 50 pmol of the corresponding small interfering RNA (siRNA; siGENOME SMARTpool from Dharmacon/ Thermo Scientific, Waltham, MA) using a monocyte Amaxa Nucleofector kit (Lonza, Basel, Switzerland) as previously described (20, 21) . Monocytes were left untreated overnight and then differentiated to macrophages as described above.
Virus production and infections
R5-tropic HIV-1 strain BaL was grown in stimulated PBMC and titrated for its use in M-CSF MDM. The macrophage tropic X4 HIV-1 92UG024 was grown in M-CSF MDM. An envelope-deficient HIV-1 NL4-3 clone encoding IRES-GFP has been previously described (22) . Virus was produced by cotransfection of the NL4-3-GFP plasmid with a plasmid expressing the envelope protein of the vesicular stomatitis virus (VSV-G) in 293T cells using Lipofectamine. Three days after transfection, supernatants were harvested, filtered, and stored at 280˚C. For the production of SIV VLP, 293T cells were cotransfected using polyethylenimine (Polysciences, Eppelheim, Germany) with pSIV3 + (23) and a VSV-G-expressing plasmid. Three days after transfection supernatants were harvested, filtered, and stored at 280˚C.
For infection experiments, macrophages were pretreated for 2 h in the presence of VLP and then infected with the VSV-NL4-3-GFP virus. Three days after transfection, cells were detached using a commercial PBS-EDTA solution, fixed, and analyzed by flow cytometry. MDM were infected with the R5 HIV-1 strain BaL between day 3 and day 7 after stimulation. Three days after infection, l00 ml culture supernatant were replaced by 100 ml fresh medium containing the corresponding stimuli. HIV production was analyzed at 7 or 14 d postinfection by ELISA HIV-p24 Ag detection (Bio-Rad Laboratories, Hercules, CA) in culture supernatants.
Quantitative PCR
DNA was extracted using a DNA extraction kit (Qiagen, West Sussex, U.K.), and proviral DNA quantifications were performed as described (21) . For relative mRNA quantification, RNA was extracted using the Qiagen RNeasy Mini Extraction kit, as recommended by the manufacturer, including the DNase I treatment step. Reverse transcriptase was performed using a high-capacity cDNA reverse transcription kit (Life Technologies, Madrid, Spain). mRNA relative levels of SAMHD1 were measured by two-step quantitative RT-PCR and normalized to b 2 -microglobulin mRNA expression using the DDCt method. Primers and DNA probes were purchased from Life Technologies.
Immunoblotting
Treated cells were rinsed in ice-cold PBS and extracts were prepared in lysis buffer, subjected to SDS-PAGE, and transferred to a nitrocellulose membrane. The following Abs were used for immunoblotting: HRP-conjugated secondary Ab (Pierce, Hercules, CA), anti-Hsp90 (Beckton Dickinson, Madrid, Spain), and anti-SAMHD1 (Abcam, Cambridge, U.K.). Protein band densities were quantified using VisionWorksLS software (UVP, Cambridge, U.K.) after acquiring the images with a ChemiDoc-It imaging system from UVP.
Viability assays
For cell viability, MDM were treated as for acute infection experiments. Measurement of cell cytotoxicity was performed by an MTT-based colorimetric assay as described before (24) . 
Statistical methods
Data were analyzed with the Prism statistical package and, unless stated otherwise, were normally distributed and expressed as mean 6 SD.
Results
HIV replication is restricted in IL-12/IL-18 MDM
Monocytes were differentiated into macrophages in the presence of M-CSF, IL-12/IL-18, GM-CSF, and IL-4 or TNF-a. As expected, infection of M-CSF MDM resulted in a strong HIV-1 p24 Ag production 7 d postinfection (Fig. 1A, filled bars) . GM-CSF or TNF-a-derived MDM led to detectable p24 Ag production in the cell supernatant (Fig. 1A, filled bars) . Conversely, IL-12/IL-18 MDM did not produce p24 Ag (Fig. 1A) , as levels were comparable to samples in which replication had been completely inhibited with 1 mg/ml reverse transcriptase inhibitor AZT, representing the background of viral input (Fig. 1A, open bars) . Moreover, virus replication was potently inhibited as measured by proviral DNA determination (Fig. 1B) . Replication of an X4, macrophage-tropic HIV-1 virus, 92UG024, was also severely restricted in IL-12/IL-18 when compared with M-CSF MDM (Fig. 1C) , indicating that inhibition was not dependent on virus coreceptor use. Importantly, when monocytes were differentiated in the presence of M-CSF and then further treated with IL-12/IL-18, macrophages became resistant to HIV-1 infection (Fig. 2A) , suggesting that IL-12/IL-18 triggered an antiviral restriction in macrophages. Conversely, treatment of IL-12/IL-18 MDM with M-CSF did not fully restore the capacity of HIV-1 to infect macrophages ( Fig. 2A) . To study how IL-12/IL-18 triggered this HIV-1 restriction, M-CSF-differentiated macrophages were treated for the days indicated with IL-12/ IL-18, washed with PBS, and then infected with the HIV-1 BaL strain for 7 d. We observed that a 24-h treatment with IL-12/IL-18 was able to induce a restriction state in M-CSF macrophages, blocking the production of HIV-1 by .90% (Fig. 2B) . Twentyfour hours infection of M-CSF MDM with HIV-1 BaL strain followed by IL-12/IL-18 or AZT treatment inhibited viral replication from subsequent infection cycles (Supplemental Fig. 1 ).
HIV coreceptor expression was not significantly affected by IL-12/IL-18 treatment, and we failed to clearly quantify CD4 expression due to macrophage autofluorescence (Supplemental Fig.  2 ). Nevertheless, IL-12/IL-18 MDM acutely infected with VSVpseudotyped HIV-1 virus were also completely resistant to infection (Supplemental Fig. 3) . Thus, these results indicate that the effect of IL-12/IL-18 was independent of virus entry but dependent on an intracellular event.
SAMHD1 mRNA levels are increased in IL-12/IL-18 MDM
We compared the mRNA levels and protein expression of SAMHD1 in M-CSF or IL12/18 MDM. Relative levels of SAMHD1 mRNA were .10-fold higher in IL-12/IL-18 MDM as compared with M-CSF MDM (Fig. 3A, filled bars) . Conversely, mRNA expression of TRIM-5a, an alternative HIV restriction factor, was not significantly different between M-CSF and IL-12/IL-18 MDM (data not shown). The increased levels of SAMHD1 in IL-12/IL-18 MDM has a reflection at the protein level, as 7-d-differentiated IL-12/IL-18 MDM showed a stronger signal than did M-CSF MDM when immunoblotting for SAMHD1 (Fig. 3B) . An anti-IFN-g-neutralizing Ab did not have a significant effect on the upregulation of SAMHD1 by IL-12/IL-18 (Fig. 3A , open bars), suggesting that an autocrine, IFN-g-dependent effect was not responsible for the upregulation of SAMHD1. Conversely, IFN-ginduced upregulation of SAMHD1 was reduced in the presence of an anti-IFN-g-neutralizing Ab (Fig. 3A, open bars) .
Degradation of SAMHD1 restores infectivity of IL-12/IL-18 MDM
RNA interference was used to confirm the role of SAMHD1 in virus restriction imposed by IL-12/IL-18. As shown in Fig. 4 , strong inhibition of SAMHD1 mRNA and protein levels were achieved after transfection of siRNA targeting SAMHD1 in M-CSF or IL-12/IL-18 MDM (Fig. 4A, 4B) . Inhibition of SAMHD1 partially increased M-CSF MDM HIV-1 infection, measured as p24 Ag production 7 d postinfection, compared with mock-transfected macrophages or macrophages transfected with a nontargeting siRNA pool (Fig. 4C) . As expected, RNA interference of HIV receptor CD4 also inhibited HIV-1 replication. siRNA-mediated inhibition of SAMHD1 allowed the replication of HIV-1 in IL-12/ IL-18 MDM that could not be detected under any other siRNA treatment or in mock-transfected cells (Fig. 4C, open bars) , suggesting that SAMHD1 was the main block for HIV-1 replication in IL-12/IL-18 MDM. Cell viability for all the conditions was measured by MTT assay and no toxic effect was detected upon any siRNA treatment (data not shown).
SAMHD1 is degraded by the lentiviral protein Vpx, expressed by HIV-2 or some SIV strains. We treated M-CSF and IL-12/IL-18 MDM with SIV VLP that deliver Vpx in the cytoplasm of the targeted cells, degrading SAMHD1 (Fig. 5A) . Two hours after starting treatment, cells were infected with a VSV-pseudotyped, GFP-expressing, NL4-3 HIV-1 virus. Three days after infection, VLP treatment increased the percentage of infected M-CSF MDM from 2.5 to 8.7% (Fig. 5B) . When we infected IL-12/IL-18 MDM, we found that the untreated cells were virtually resistant to the infection (Fig. 5C ), but the treatment of the cells with VLP restores the infectivity, reaching 18.5% of GFP + cells (Fig. 5C ). M-CSF-treated cells are already susceptible to infection and the effect of Vpx may not be as profound as in cells in which HIV-1 cannot infect, explaining the lower levels of GFP + cells reached by M-CSF MDM compared with IL-12/IL-18 MDM when both are treated with VLPs. We conclude that degradation of SAMHD1 by two different mechanisms restored HIV-1 infectivity in IL-12/IL-18 MDM, strongly indicating that SAMHD1 is the major restriction factor behind the IL-12/IL-18-induced MDM resistance to HIV-1 infection. 
Discussion
Monocytes and macrophages have different susceptibility to infection by HIV depending on their origin, stage of differentiation, and environment. In this study we have shown that whereas human primary macrophage differentiated with M-CSF, GM-CSF/IL-4, or TNF-a become susceptible to HIV infection, stimulation of macrophages with a combination of IL-12 and IL-18 prevented or blocked a productive infection by HIV-1. Furthermore, 24 h stimulation with IL-12 and IL-18 was sufficient to make the cells resistant to HIV-1 infection.
The fact that macrophages can switch from a permissive to a nonpermissive state suggested that IL-12/IL-18 was inducing the expression or activation of a restriction factor. When we analyzed expression levels of SAMHD1, we found that mRNA and protein levels were increased in IL-12/IL-18 MDM (Fig. 3) . We cannot disount that other factors may also be upregulated in IL-12/IL-18 MDM, especially when taking into account that we have previously shown that IL-12/IL-18 stimulation induced IFN-g secretion that, in turn, could stimulate antiviral genes in an autocrine manner (6) . Moreover, protein expression as measured by Western blot did not necessarily reflect the increased expression measured by mRNA quantification, suggesting that activation/deactivation of already expressed SAMHD1 could also be a mechanism affected by IL-12/ IL-18. However, we have clearly demonstrated that the main HIV-1 restriction in IL-12/IL-18 MDM is due to SAMHD1, as RNA interference or Vpx-mediated degradation of SAMHD1 completely reverted the restriction in the IL-12/IL-18 (Figs. 4, 5) .
The role of SAMHD1 in restricting HIV-1 replication in myeloid cells and lymphocytes has gained wide interest, but little is known about its regulation mechanism. SAMHD1 has been identified as an IFN-g-dependent gene (25) (Fig. 3A) , and IL-12/IL-18 macrophages produce significant amounts of IFN-g (6) . Then, we investigated whether SAMHD1 increased mRNA levels were induced by the IL-12/IL-18-stimulated production of IFN-g acting in an autocrine manner. However, we have found that IL-12/IL-18 stimulation may increase SAMHD1 mRNA and protein levels independently of IFN-g (Fig. 3A) . To our knowledge, this is the first demonstration that SAMHD1 function can be modulated through an IFN-g-independent pathway but, nevertheless, dependent on cytokines associated to the M1/ Th1 differentiation process (4, 26) . IL-12 and IL-18 are produced by APCs in response to the recognition of a pathogen. Furthermore, neutrophils produce very high levels of IL-12, and IL-18 is also produced by epithelial and endothelial cells, indicating that they might have a role in tissues rich in macrophage lung and mucosal tissues. IL-12 and IL-18 receptors are expressed in monocytes, macrophages, and lymphocytes (27) (28) (29) . Production of IL-12 is thought to link innate immune responses with adaptive responses, leading to Th1 polarization of T lymphocytes. Therefore, the role of these and other cytokines in T cell virus restriction remains to be explored. SAMHD1 has been also described as a restriction factor in resting CD4 + T lymphocytes, which is lost when lymphocytes are activated (30, 31) . Strikingly, no changes in SAMHD1 expression levels have been observed between resting and activated CD4 + lymphocytes (Refs. 30, 31, and E. Pauls and J. Este, unpublished observations), implying that additional regulation mechanisms may modulate SAMHD1 function. Therefore, we cannot exclude that IL-12/IL-18 may be activating some other mechanism of control of SAMHD1.
Finally, we have previously observed that IL-12 and IL-18 receptors are upregulated in CD4 + T resting lymphocytes of HIV-1-infected patients, suggesting that deregulation of the IL-12 and IL-18 pathways may play a role in the immunopathogenesis of HIV-1 infection (19) . It is tempting to think that IL-12 and IL-18 signaling may link cell polarization to HIV-1 susceptibility through the regulation of SAMHD1. The observation that mutations in SAMHD1 are associated with the Aicardi-Goutières syndrome, an autoimmune illness characterized by elevated IFN levels (32) , suggests that SAMHD1 may play a role in controlling or limiting the innate immune response to an unknown agent. SAMHD1 capacity to limit the pool of dNTPs may lead to abortive reverse transcription and the accumulation of intracellular DNA, which in turn may trigger an innate cellular response leading to apoptosis (33) . How IL-12 and IL-18 may modulate this response through the regulation of SAMHD1 should be addressed in the future.
